Please assess the completion status of the following clinical trial:

Trial Title: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients, 18 to 80 years of age at Visit 0~* Women of childbearing potential must have a negative pre-treatment pregnancy test, negative monthly pregnancy test, and must use reliable methods of contraception according to the Risk Evaluation Mitigation Strategies (REMS) guidance~* Symptomatic pulmonary arterial hypertension, World Health Organization Group 1 with a pulmonary vascular resistance (PVR) \>300 dyn\*sec\*cm-5, mean pulmonary artery pressure (PAP mean) ≥25 mmHg, and pulmonary capillary wedge pressure (PCWP) ≤15 mmHg as assessed by right heart catheterization within 6 months prior to Screening (Visit 0)~* PAH of the following types:~Idiopathic (IPAH) Familial (FPAH)~Associated with PAH (APAH) due to:~Connective tissue disease Congenital heart disease, but only if patient underwent surgical repair more than one year before enrollment Anorexigen or amphetamine use Portal hypertension with liver cirrhosis~* Not treated with PAH-specific pulmonary medications within 14 days of Screening (Visit 0)~* 6MWD between 150 meters and 450 meters~Exclusion Criteria:~* Patients who are pregnant~* Patients currently on nitrate and/or nitric oxide (NO) donor therapy; patients currently taking phosphodiesterase 5 (PDE5) inhibitors (such as sildenafil, tadalafil, vardenafil) and non-specific PDE inhibitors (theophylline, dipyridamole)~* Non-WHO group 1 Pulmonary Hypertension~* Severe restrictive lung disease~* History of uncontrolled high blood pressure or hypotension~* A medical disorder, condition, or history that in the opinion of the Investigator would impair their ability to participate or complete this study~* Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Riociguat 0.5mg to 2.5 mg (Type: EXPERIMENTAL): Single arm, open label

Based on this trial design, predict the completion outcome and termination type (if applicable).